Moleculin Announces Publication Of Data From Successful European Phase 1 Trial Evaluating Annamycin As Single Agent Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
Portfolio Pulse from Happy Mohamed
Moleculin Biotech, Inc. (NASDAQ:MBRX) has announced the publication of data from its successful European Phase 1 clinical trial evaluating Annamycin as a single agent treatment for relapsed or refractory Acute Myeloid Leukemia (AML). The trial showed no evidence of cardiotoxicity in any subject and an 80%/60% ORR/CRi rates in the last single agent cohort. Annamycin is currently being evaluated in a Phase 1b/2 study in combination with Cytarabine for the treatment of AML.
July 13, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moleculin Biotech's successful Phase 1 trial results for Annamycin could potentially boost investor confidence in the company's AML program. The absence of cardiotoxicity and high response rates are positive indicators for the drug's future development.
The successful Phase 1 trial results for Annamycin, with no evidence of cardiotoxicity and high response rates, are positive indicators for the drug's future development. This could potentially boost investor confidence in Moleculin Biotech's AML program, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100